NUT midline carcinoma as a primary lung tumor treated with anlotinib combined with palliative radiotherapy: a case report

Diagnostic Pathology

Xing Lin¹  Jin Jiang²  Yikun Ren²  Chengping Xu³ 

[1]Department of Biological Immunotherapy, Chongqing University Cancer Hospital, Chongqing Cancer Institute, Chongqing Cancer Hospital, Shapingba District, 400030, Chongqing, China

[2]Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, 400016, Chongqing, China

[3]Department of Pathology, The Southwest Hospital, the Southwest Hospital of Army Medical University, 400038, Chongqing, China

关键词: NUT midline carcinoma;    Primary lung tumor;    Anlotinib;    Palliative radiotherapy;    Case report;   

DOI  :  10.1186/s13000-021-01188-y

来源: Springer

【 摘 要 】

BackgroundNUT (nuclear protein in testis) midline carcinoma (NMC) is a rapidly progressive tumor arising from midline structures. Recent cases have reported that the poor prognosis with a median survival of 6.7 months and a 2 years overall survival of 19% due to limited treatment. Based on the effect of arotinib on inhibiting tumor growth and angiogenesis. We present one patient case treated with anlotinib and radiotherapy.Case presentationHere, we describe a 33-year old patient who complained of cough and chest pain and was diagnosed as a pulmonary NMC through CT scan, FISH and immunohistochemistry. In addition, we initially demonstrated that anlotinib combined with palliative radiotherapy could significantly prevent the tumor growth in a pulmonary NMC.ConclusionThe report indicated that anlotinib combined with palliative radiotherapy could inhibit the tumor progression in a pulmonary NMC, which may provide a combined therapy to pulmonary NMC in the future.

【 授权许可】

CC BY